Evidence map›Paper›PMID 39766302›Full record

ArticleBiomolecules2024

Rapid Detection of

William Middlezong, Victoria Stinnett, Michael Phan, Brian Phan, Laura Morsberger, Melanie Klausner, Jen Ghabrial, Natalie DeMetrick, Jing Zhu, Trisha James and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biomolecules, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Atypical singleBlood neoplasia · 2026
    Article
  3. Article
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

William MiddlezongKrieger School of Arts and Sciences, Johns Hopkins University, Baltimore, MD 21218, USA.
Victoria StinnettDepartment of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.ORCID 0000-0003-0317-1385
Michael PhanKrieger School of Arts and Sciences, Johns Hopkins University, Baltimore, MD 21218, USA.
Brian PhanDepartment of Biology, The College of William and Mary, Williamsburg, VA 23186, USA.
Laura MorsbergerDepartment of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.
Melanie KlausnerDepartment of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.
Jen GhabrialDepartment of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.ORCID 0000-0002-1993-4087
Natalie DeMetrickDepartment of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.
Jing ZhuDepartment of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.
Trisha JamesDepartment of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.
Aparna PallavajjalaDepartment of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.
Christopher D GockeDepartment of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.ORCID 0000-0002-9541-2192
Maria R BaerDepartment of Medicine, University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore, MD 21201, USA.
Ying S ZouDepartment of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.ORCID 0000-0003-2787-1917

Funding

QAQC Johns Hopkins Institute for Clinical and Translational ResearchUL1TR003098 · NCATS · JOHNS HOPKINS UNIVERSITY · PI FORD, DANIEL ERNEST · 2019 to 2023
$57.7M
Johns Hopkins Institute for Clinical and Translational Research (ICTR) ATIP grantNCATS NIH HHS UL1 TR003098
6 · The paper itself

Abstract

Acute promyelocytic leukemia (APL) accounts for approximately 10-15% of newly diagnosed acute myeloid leukemia cases and presents with coagulopathy and bleeding. Prompt diagnosis and treatment are required to minimize early mortality in APL as initiation of all-trans retinoic acid therapy rapidly reverses coagulopathy. The

Indexed as

CRISPR-Cas SystemsLeukemia, Promyelocytic, AcuteNanopore SequencingOncogene Proteins, FusionHumansPromyelocytic Leukemia ProteinRetinoic Acid Receptor alphaOncogene Proteins, FusionPromyelocytic Leukemia Proteinpromyelocytic leukemia-retinoic acid receptor alpha fusion oncoproteinRARA protein, humanRetinoic Acid Receptor alphaacute promyelocytic leukemiaadaptive samplingCRISPR/Cas9nanopore sequencingPML::RARA fusions

Identifiers

PMID39766302
PMCPMC11674480

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.